125-L-serine-2-133-interleukin 2 (human Reduced)
125-L-serine-2-133-interleukin 2 (human Reduced) Uses, Dosage, Side Effects, Food Interaction and all others data.
125-L-serine-2-133-interleukin 2 (human Reduced), a lymphokine, is produced by recombinant DNA technology using a genetically engineered E. coli strain containing an analog of the human interleukin-2 gene. Genetic engineering techniques were used to modify the human IL-2 gene, and the resulting expression clone encodes a modified human interleukin-2. This recombinant form differs from native interleukin-2 in the following ways: a) 125-L-serine-2-133-interleukin 2 (human Reduced) is not glycosylated because it is derived from E. coli; b) the molecule has no N-terminal alanine; the codon for this amino acid was deleted during the genetic engineering procedure; c) the molecule has serine substituted for cysteine at amino acid position 125.
Used to treat renal cell carcinoma, 125-L-serine-2-133-interleukin 2 (human Reduced) induces the enhancement of lymphocyte mitogenesis and stimulation of long-term growth of human interleukin-2 dependent cell lines, the enhancement of lymphocyte cytotoxicity, the induction of killer cell (lymphokine-activated (LAK) and natural (NK)) activity; and the induction of interferon-gamma production. IL-2 is normally produced by the body, secreted by T cells, and stimulates growth and differentiation of T cell response. It can be used in immunotherapy to treat cancer. It enhances the ability of the immune system to kill tumor cells and may interfere with blood flow to the tumor.
| Trade Name | 125-L-serine-2-133-interleukin 2 (human Reduced) |
| Availability | Prescription only |
| Generic | Aldesleukin |
| Aldesleukin Other Names | 125-L-serine-2-133-interleukin 2 (human reduced), Aldesleukin, Aldesleukina, ILT-101, ILT101, Interleukin-2 aldesleukin, Interleukin-2(2-133),125-ser, Recombinant human interleukin-2, Recombinant interleukin-2 human |
| Related Drugs | Keytruda, pembrolizumab, Avastin, bevacizumab, Opdivo, nivolumab, atezolizumab, Afinitor, ipilimumab, Yervoy |
| Type | |
| Formula | C690H1115N177O202S6 |
| Weight | 15314.8 Da |
| Groups | Approved |
| Therapeutic Class | |
| Manufacturer | |
| Available Country | |
| Last Updated: | September 19, 2023 at 7:00 am |
Uses
125-L-serine-2-133-interleukin 2 (human Reduced) is a recombinant analog of interleukin-2 used to induce an adaptive immune response in the treatment of renal cell carcinoma.
For treatment of adults with metastatic renal cell carcinoma.
125-L-serine-2-133-interleukin 2 (human Reduced) is also used to associated treatment for these conditions: High Risk Neuroblastoma, Metastatic Melanoma, Metastatic Renal Cell Carcinoma
How 125-L-serine-2-133-interleukin 2 (human Reduced) works
125-L-serine-2-133-interleukin 2 (human Reduced) binds to the IL-2 receptor which leads to heterodimerization of the cytoplasmic domains of the IL-2R beta and gamma(c) chains, activation of the tyrosine kinase Jak3, and phosphorylation of tyrosine residues on the IL-2R beta chain. These events led to the creation of an activated receptor complex, to which various cytoplasmic signaling molecules are recruited and become substrates for regulatory enzymes (especially tyrosine kinases) that are associated with the receptor. These events stimulate growth and differentiation of T cells.
Food Interaction
No interactions found.125-L-serine-2-133-interleukin 2 (human Reduced) Drug Interaction
Moderate: quinapril, quinapril, nifedipine, nifedipine, zolpidem, zolpidemUnknown: paclitaxel protein-bound, paclitaxel protein-bound, acetaminophen, acetaminophen, aspirin, aspirin, rabeprazole, rabeprazole, pioglitazone, pioglitazone, rosuvastatin, rosuvastatin, ketorolac, ketorolac
125-L-serine-2-133-interleukin 2 (human Reduced) Disease Interaction
Major: autoimmune diseases, cardiovascular disease, edema, hepatic dysfunction, hypotension, myelosuppression, neutrophil dysfunction, organ transplant, pulmonary dysfunction, renal dysfunction, seizuresModerate: mental status changes
Volume of Distribution
0.18 l/kg
Half Life
13 min-85 min
Elimination Route
The pharmacokinetic profile of Proleukin is characterized by high plasma concentrations following a short IV infusion, rapid distribution into the extravascular space and elimination from the body by metabolism in the kidneys with little or no bioactive protein excreted in the urine. Following the initial rapid organ distribution, the primary route of clearance of circulating proleukin is the kidney. Greater than 80% of the amount of Proleukin distributed to plasma, cleared from the circulation and presented to the kidney is metabolized to amino acids in the cells lining the proximal convoluted tubules.
Innovators Monograph
You find simplified version here 125-L-serine-2-133-interleukin 2 (human Reduced)
